Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 582-586, November 2005

Radiotherapy plus adjuvant goserelin improves survival in men with poor prognosis prostate cancer:☆☆☆☆☆☆

Abstracted from: Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285–90.

  • Mack Roach III, MD, FACR

      Affiliations

    • Corresponding Author InformationTel.: +1 415 353 7175; fax: +1 415 353 9883.

Professor of Radiation Oncology and Urology, Departments of Radiation Oncology and Urology, University of California San Francisco, UCSF Comprehensive Cancer Center, San Francisco, CA, United States

published online 02 November 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: National Institute of Health, Bethesda, USA.

☆☆ For correspondence: Miljenko V Pilepich, Department of Radiation Oncology, University of California, Los Angeles, School of Medicine, P.O. Box 2515, Los Angeles, CA 90265, United States. Tel: +310 597 5147; fax: +310 457 3451; e-mail: mpilepich@mednet.ucla.edu.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(05)00137-4

doi:10.1016/j.ctrv.2005.08.002

Cancer Treatment Reviews
Volume 31, Issue 7 , Pages 582-586, November 2005

Article Tools